Drugs / Onfekafusp alfa
Onfekafusp alfa
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05304663 | Jun 2022 → Dec 2024 | glioblastoma | Philogen S.p.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04032964 | Sep 2019 → Dec 2024 | soft tissue sarcoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04573192 | Feb 2021 → Mar 2025 | glioblastoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04443010 | Jan 2021 → Oct 2026 expected | glioblastoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03779230 | May 2019 → Jun 2023 | brain glioma | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07227350 | Jun 2026 → Feb 2031 expected | skin basal cell carcinoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT07227870 | Feb 2026 → Feb 2031 expected | skin basal cell carcinoma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07228442 | Feb 2026 → Feb 2031 expected | skin squamous cell carcinoma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07120984 | Jan 2026 → Jan 2029 expected | glioma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06284590 | Jul 2024 → Jul 2028 expected | metastatic melanoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT06336291 | May 2024 → Jun 2026 overdue | glioblastoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05329792 | Mar 2023 → Jun 2024 | Kaposi's sarcoma, cutaneous neuroendocrine carcinoma, keratoacanthoma, primary cutaneous T-cell lymphoma +3 | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT04362722 | Sep 2020 → Sep 2024 | basal cell carcinoma, skin squamous cell carcinoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT04733183 | Aug 2020 → Dec 2025 overdue | soft tissue sarcoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03420014 | Dec 2018 → Dec 2024 | leiomyosarcoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT02076633 | Dec 2012 → May 2015 | cutaneous melanoma | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04650984 | Nov 2017 → Dec 2025 | soft tissue sarcoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02938299 | Jul 2016 → Oct 2024 overdue | melanoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onfekafusp alfa | “Drug: onfekafusp alfa” NCT04733183 ↗ |
| Known as | Fibromun | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298007 ↗ |
| Known as | L19TNF | “L19TNF is a fully human fusion protein consisting of human tumor necrosis factor (TNF)-α fused to the L19 antibody in scFv format, specific to the extra-domain B of fibronectin.” NCT04573192 ↗ |
| Known as | Onfekafusp alfa component of daromun l19tnf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298007 ↗ |
| Modality | Protein / enzyme biologic | “L19TNF is a recombinant fusion protein” NCT02076633 ↗ |
| Route | Other | “intratumoral injections” NCT02076633 ↗ |